Lilly’s phase III retatrutide wins in A1C dips and weight loss for T2D patients
· bioworld
AI Briefing
- Retruttide shows promise in phase III trials for T2D patients
- Study results indicate statistically significant reductions in A1C levels and weight loss
- Pharma companies await FDA approval for potential new treatment for type 2 diabetes
Advertisement